Cefepime Versus Carbapenem Therapy for the Treatment of Invasive Infections With Inducible Chromosomal AmpC-Producing Enterobacterales: A Systematic Review and Meta-analysis
Open Forum Infectious Diseases · 30.06.2025 · 12 (7)
DOI: 10.1093/ofid/ofaf413 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 14.07.2025. Verfasst von Hao Min Cheo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, National Centre for Infectious Diseases, Singapore. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The optimal antibiotic choice for AmpC-producing Enterobacterales bloodstream infections (BSIs) and complicated urinary tract infections (cUTIs) remains to be clearly defined. Guidance from the Infectious Diseases Society of America recommends cefepime as first-line therapy, based on observational studies. We conducted a systematic review and meta-analysis to compare the clinical outcomes of cefepime versus carbapenems in patients with infections caused by AmpC-producing Enterobacterales.
Methods
A systematic search was conducted across Medline, Embase, Cochrane, and Scopus databases to identify studies comparing cefepime and carbapenems for the treatment of BSIs and cUTIs due to AmpC-producing Enterobacterales. Eligible studies reported all-cause mortality as the primary outcome. Secondary outcomes included clinical and microbiological cure, relapse, and adverse events. A random-effects meta-analysis was performed to estimate pooled odds ratios (ORs) with 95% confidence intervals (CIs).
Results
Seven studies on BSI encompassing 1099 patients were included, with 479 receiving cefepime and 620 receiving carbapenem as definitive antibiotics. There were no studies on cUTI. No statistically significant difference in all-cause mortality was observed between cefepime and carbapenem treatment (log OR, 0.15 [95% CI, −.33 to .64]; P = .54), although a nonsignificant trend favored cefepime, particularly in the subgroup of larger observational studies (n ≥ 50 patients) and more recent studies (published after 2019). Relapse rates were also comparable between the 2 groups (log OR, 0.39 [95% CI, −.25 to 1.03]; P = .23).
Conclusions
In line with published guidance, treatment outcomes with cefepime did not differ significantly from carbapenems for AmpC-producing BSIs. However, randomized controlled trials are needed to validate these findings. Clinical Trials Registration. PROSPERO: CRD42025634449.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, National Centre for Infectious Diseases, Singapore.
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Division of Infectious Diseases, Department of Medicine, National University Hospital, National University Health System, Singapore.
- Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
ORCID-Profile: Darren Yan Kit Ho, Lin Pin Koh, Jinghao Nicholas Ngiam
Zitieren
APA
Cheo, H. M., Ho, D. Y. K., Koh, L. P., Koh, M. C. Y., Ngiam, J. N., & Lye, D. C. B. (2025). Cefepime Versus Carbapenem Therapy for the Treatment of Invasive Infections With Inducible Chromosomal AmpC-Producing Enterobacterales: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 12(7). https://doi.org/10.1093/ofid/ofaf413
Vancouver
Cheo HM, Ho DYK, Koh LP, Koh MCY, Ngiam JN, Lye DCB. Cefepime Versus Carbapenem Therapy for the Treatment of Invasive Infections With Inducible Chromosomal AmpC-Producing Enterobacterales: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases. 2025;12(7). doi:10.1093/ofid/ofaf413
BibTeX
@article{Cheo2025,
author = {Cheo, Hao Min and Ho, Darren Yan Kit and Koh, Lin Pin and Koh, Matthew Chung Yi and Ngiam, Jinghao Nicholas and Lye, David Chien Boon},
title = {Cefepime Versus Carbapenem Therapy for the Treatment of Invasive Infections With Inducible Chromosomal AmpC-Producing Enterobacterales: A Systematic Review and Meta-analysis},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {7},
doi = {10.1093/ofid/ofaf413}
}
EUVIMED